Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.64 |
| ▸ | CYP46A1 | Q9Y6A2 | 2/20 | 0.63 |
| ▸ | OSBP | P22059 | 3/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | RORC | P51449 | 1/20 | 0.59 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.59 |
| ▸ | GBA1 | P04062 | 2/20 | 0.53 |
| ▸ | UGCG | Q16739 | 2/20 | 0.53 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.53 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.53 |
| ▸ | NPC1L1 | Q9UHC9 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.51 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15702070 | 1.00 | POLA1 (0.64) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL26032459 | 1.00 | POLA1 (0.64) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL17236066 | 1.00 | POLA1 (0.64) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL17665325 | 1.00 | POLA1 (0.64) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL2334979 | 1.00 | POLA1 (0.64) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL15826833 | 1.00 | POLA1 (0.64) | POLA1CYP46A1OSBPUSP2LMNA | |
| Hydrochloric Acid SCHEMBL2403217 | 0.99 | POLA1 (0.63) | POLA1CYP46A1OSBPUSP2LMNA | |
| Hydrochloric Acid SCHEMBL2403220 | 0.99 | POLA1 (0.63) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL26032465 | 0.99 | POLA1 (0.65) | POLA1CYP46A1OSBPUSP2LMNA | |
| SCHEMBL10283033 | 0.97 | POLA1 (0.64) | POLA1CYP46A1OSBPUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11564971-B2 | Hyaluronic acid derivative having amino acid and steryl group introduced thereinto | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-31 | — | — | US | disclosed |
| US-9968647-B2 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9968647-B2 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2018-05-15 | — | — | US | disclosed |
| EP-2894173-B1 | HYALURONIC ACID DERIVATIVE HAVING AMINO ACID AND STERYL GROUP INTRODUCED THEREINTO | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-04-19 | — | — | EP | disclosed |
| EP-3147367-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | F. Hoffmann-La Roche AG (CH) | 2017-03-29 | — | — | EP | disclosed |
| US-20170022505-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-01-26 | — | — | US | disclosed |
| US-20170022505-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2017-01-26 | — | — | US | disclosed |
| EP-2658981-B1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-2658982-B1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2016-04-20 | — | — | EP | disclosed |
| US-9301990-B2 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-20150231268-A1 | HYALURONIC ACID DERIVATIVE HAVING AMINO ACID AND STERYL GROUP INTRODUCED THEREINTO | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-08-20 | — | — | US | disclosed |
| EP-2894173-A1 | HYALURONIC ACID DERIVATIVE HAVING AMINO ACID AND STERYL GROUP INTRODUCED THEREINTO | Chugai Seiyaku Kabushiki Kaisha (JP) | 2015-07-15 | — | — | EP | disclosed |
| EP-2360188-B1 | HYALURONIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | NAT UNIV CORP TOKYO MED & DENT (JP) | 2014-09-17 | — | — | EP | disclosed |
| US-8759322-B2 | Hyaluronic acid derivative and pharmaceutical composition thereof | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY (JP) | 2014-06-24 | — | — | US | disclosed |
| US-20140135380-A1 | Small molecule conjugates for intracellular delivery of nucleic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135381-A1 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135381-A1 | Small molecule conjugates for intracellular delivery of biologically active compounds | HOFFMANN-LA ROCHE INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135380-A1 | Small molecule conjugates for intracellular delivery of nucleic acids | HOFFMANN-LA ROCHE INC. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20110212901-A1 | HYALURONIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNVERSITY (JP) | 2011-09-01 | — | — | US | disclosed |
| EP-2360188-A1 | HYALURONIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | National University Corporation Tokyo Medical and Dental University (JP) | 2011-08-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135381-A1 | Small molecule conjugates for intracellular delivery of biologically active compounds | SNRPE, PHAX, SNRPA | POLA1 2007/4885CYP46A1 3372/4885OSBP 1914/4885 |
| US-20140135380-A1 | Small molecule conjugates for intracellular delivery of nucleic acids | SNRPE, PHAX, SNRPA | POLA1 867/4885CYP46A1 3741/4885OSBP 2267/4885 |
| US-20150231268-A1 | HYALURONIC ACID DERIVATIVE HAVING AMINO ACID AND STERYL GROUP INTRODUCED THEREINTO | CD44, DAO, FUT6 | POLA1 4461/4885CYP46A1 1464/4885OSBP 4572/4885 |
| US-20170022505-A1 | SMALL MOLECULE CONJUGATES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE COMPOUNDS | SNRPE, PHAX, SNRPA | POLA1 2007/4885CYP46A1 3372/4885OSBP 1914/4885 |
| US-20110212901-A1 | HYALURONIC ACID DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF | CD44, H1-0, F12 | POLA1 3182/4885CYP46A1 2201/4885OSBP 4838/4885 |
| US-11564971-B2 | Hyaluronic acid derivative having amino acid and steryl group introduced thereinto | CD44, DAO, FUT6 | POLA1 4461/4885CYP46A1 1464/4885OSBP 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.